Kaplan Fox Announces a Securities Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) - Investors Encouraged to Contact the FirmNewsfile Corp • 11/09/26
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS LawBusiness Wire • 11/09/26
MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLPGlobeNewsWire • 11/07/26
Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLPPRNewsWire • 11/07/26
NASDAQ: MDGL INVESTIGATION ALERT: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLPBusiness Wire • 11/06/26
Lost Money on Madrigal Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 8.1% Share Price DropBusiness Wire • 11/06/26
Did You Lose Money on Madrigal Pharmaceuticals, Inc. Stock? The Law Offices of Howard G.Business Wire • 11/06/26
Kaplan Fox & Kilsheimer LLP Encourages Madrigal Pharmaceuticals, Inc. (MDGL) Investors to Contact the Firm Regarding Potential Securities Law ViolationsNewsfile Corp • 11/06/26
Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R.Business Wire • 11/05/26
Kaplan Fox & Kilsheimer LLP Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding Potential Securities Law ViolationsGlobeNewsWire • 11/05/26
Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with RezdiffraGlobeNewsWire • 11/05/26
MADRIGAL PHARMACEUTICALS, INC. INVESTIGATION: MDGL Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsGlobeNewsWire • 11/04/26
Madrigal Q3 Earnings: Why I'm Upgrading The Stock Again In 2026, This Time To BuySeeking Alpha • 11/04/26
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/03/26
Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 10/27/26
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASHGlobeNewsWire • 10/27/26
Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding FranchiseSeeking Alpha • 10/20/26
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026GlobeNewsWire • 10/20/26
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk VariantsGlobeNewsWire • 10/06/26
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?The Motley Fool • 09/10/26